DCDong Chang

Dong Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dong Chang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Cui

    Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • Chunquan Liu

    Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Huansong Yang

    Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Shuai Song

    Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    2 shared publications
  • Bowen Li

    Department of Thoracic Surgery, Beijing Friendship Hospital Capital Medical University Beijing China

    1 shared publication
  • Changlei Li

    Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication

Latest Publications

  • Open Access

    Spatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma

    by Yefeng Shen, Yunlei Ma, Huansong Yang, Jing Kang, Jing Li, Xinchun Duan, Chunquan Liu, Jian Song, Dong Chang, Yong Cui

    Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after neoadjuvant therapy using single-cell transcriptomic profiling, spatial transcriptomics, and spatial metabolomic imaging. This multilayered, same-sample framework revealed extensive remodeling of the tumor microenvironment, including enhanced immune activation and marked changes in the spatial organization of major cellular populations. Notably, CXCL10 increased the intratumoral proportion of CD8⁺ T cells, promoted their cytotoxic activation, and enhanced T-cell–mediated tumor elimination both in vitro and in vivo. Genetic silencing or pharmacological inhibition of CXCR3 attenuated these effects and diminished the therapeutic benefit of anti-PD1 treatment, supporting a functional role for the CXCL10–CXCR3 axis in modulating immunotherapy efficacy. Spatial metabolomics further revealed pronounced remodeling of ornithine metabolism in malignant regions, characterized by suppression of the urea cycle, potential involvement of a glutamate/proline-linked ornithine pathway, and enhanced polyamine synthesis. An ornithine metabolism-related gene signature was strongly associated with poor prognosis in the TCGA-ESCC cohort, while pharmacological inhibition of ornithine decarboxylase enhanced the antitumor efficacy of anti-PD1 therapy in vivo. Together, these findings provide a spatial multi-omics atlas of ESCC following nICT and identify the CXCL10–CXCR3 axis and ornithine-centered metabolic remodeling as potentially actionable immune and metabolic features associated with treatment response.

  • Open Access

    Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes

    by Peng Song, Zhiyuan Yao, Shuai Song, Zengjin Wen, Xiao Sun, Changlei Li, Huansong Yang, Wenjie Jiao, Yong Cui, Dong Chang

    Background: Inflammatory indexes are increasingly being considered to predict treatment response in tumors. This study aimed to investigate the efficacy of serum inflammatory indexes in predicting pathological response in patients with esophageal squamous cell carcinoma (ESCC) receiving anti-PD-1 neoadjuvant immunochemotherapy (NICT). Methods: We retrospectively collected clinical and laboratory data from 116 ESCC patients who received NICT. We set three outcome variables: pathologic complete response (PCR), good response (GR), and response (R). We assessed between-group differences in inflammation indexes and their diagnostic efficacy. Independent diagnostic markers were filtered using least absolute shrinkage and selection operator (LASSO) logistic regression and multivariable analysis, and the corresponding nomograms for PCR and GR were constructed, respectively. Receiver operating characteristic curves (ROC) and calibration curves assessed the efficiency and accuracy of the models. Decision curve analysis (DCA) and clinical impact curves (CIC) evaluated the clinical value. Moreover, we internally validated the predictive model with a random sample of 30% of patients. Results: The prognostic nutritional index (PNI) predicted a cutoff value of 53.585 for PCR with an area under curve (AUC) value of 0.720, a cutoff value of 47.85 for GR with an AUC of 0.723, a cutoff value of 47.85 for R with an AUC of 0.629. Smoking and PNI were independent predictors of PCR, platelet-to-lymphocyte ratio (PLR) and PNI were independent predictors of GR, and PNI was an independent predictor of R. We built PNI-based nomograms to predict PCR and GR with AUC values of 0.795 and 0.763 for the training cohort and 0.907 and 0.757 for the validation cohort, respectively. The predicted and actual results of the calibration curves for both the training and validation groups showed good agreement, with Brier scores below 0.25. Conclusion: High PNI value is a shared independent predictor of achieving PCR, GR, and R in ESCC patients receiving anti-PD1 NICT. PNI-based diagnostic models can be used as a practical tool to identify ideal patients for personalized clinical decisions.


  • Open Access

    Rare cystic lymphangioma in the chest wall of an adult patient: A case report and comprehensive review of the literature

    by Shuai Song, Dong Chang, Hao Li, Bowen Li, Kaikai Xu, Chunquan Liu, Yong Cui

    Lymphangiomatosis is a rare, benign, hyperproliferative hamartoma composed of dilated lymphatic vessels. Cystic lymphangioma (CL) in the chest wall in an adult patient is rare, but we focus on this type of patient in our present case study. A 54‐year‐old female patient with a painless mass in her chest wall went without treatment for two years following diagnosis. After consenting to treatment, Doppler color flow imaging (DCFI), chest CT, and MRI revealed a cystic lesion with multiple thin septula in the left chest. Surgical resection was performed, and histopathological examination identified a cystic lymphangioma. The patient did not experience recurrence during the follow‐up period.


  • Case report of achalasia secondary to a lung carcinoma of the mediastinal type

    by Hu Jian, Gong Ming, Song Shuai, Wang Tianyou, Chang Dong

    Pseudo‐ or secondary achalasia may mimic primary achalasia upon radiological examination and may be difficult to diagnose. It is usually due to a cancer or metastases involving the gastroesophageal junction. We present the case of a 53‐year‐old woman with recent onset of dysphagia, and with typical findings suggesting primary achalasia. We found a 4‐cm mediastinal tumor invading the lower esophagus, which was proven to be a metastasis from a lung carcinoma. The patient was treated with surgery, chemotherapy and radiotherapy. In patients with a new onset of achalasia symptoms, keeping in mind the possibility of an underlying cancer is important.


  • New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice

    by Shuai Song, Dong Chang, Yong Cui, Jian Hu, Min Gong, Kai Ma, Fang Ding, Zhi-Hua Liu, Tian-You Wang

    Subcutaneous xenograft is a common method to establish animal models of human esophageal squamous cell carcinoma (ESCC). However, the growth microenvironment of transplanted tumors is different from primary tumors. Orthotopic implantation models can provide more biologically relevant context in which to study the disease. So far, an orthotopic implantation model of ESCC has rarely been reported. The human ESCC cell line KYSE30 was transfected with pLVX-Luciferase plasmids. KYSE30-Luciferase cells were isolated and injected into the flanks of nude mice to develop a subcutaneous tumor. An orthotopic implantation model was established using the fragments derived from the subcutaneous tumor. Fluorescence imaging was used to observe the development of the orthotopic implanted tumor. Hematoxylin and eosin staining was performed to evaluate the invasion and metastasis of the tumor. KYSE30 cells were successfully transfected with pLVX-Luciferase plasmids. A primary tumor was developed in all mice. The mice experienced body weight loss. The implanted tumor infiltrated into the esophageal muscularis propria. However, neither distant organ nor lymph node metastasis was found. The progression of the primary tumor was monitored by in vivo fluorescence imaging. The orthotopic implantation model can be established by sewing the fragments of human ESCC to the abdominal esophagus of a nude mouse. The progression of an orthotopic implantation tumor can be monitored in real time by in vivo fluorescence imaging.